Statins Inhibit Rho Kinase Activity in Patients with Atherosclerosis

Overview

Journal Atherosclerosis

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2009 Jan 27

PMID 19167712

Citations 67

Authors

Anju Nohria

Adnan Prsic

Ping-Yen Liu

Ryuji Okamoto

Mark A Creager

Andrew Selwyn

James K Liao

Peter Ganz

Affiliations

Soon will be listed here.

Abstract

Background: In addition to inhibiting cholesterol synthesis, statins (HMG-CoA reductase inhibitors) decrease the formation of isoprenoid intermediates required for the activation of key signaling pathways, including Rho/Rho kinase (ROCK). In experimental settings, statins inhibit ROCK and reverse vascular dysfunctions in atherosclerosis, independent of cholesterol reduction. It is not known whether statins inhibit ROCK activity in humans with atherosclerosis.

Methods: We investigated 35 patients with stable atherosclerosis in a randomized, double-blind study comparing treatment with high-dose (80mg/d) or low-dose (10mg/d) atorvastatin to placebo for 28 days. Blood samples for leukocyte ROCK activity, fasting lipids, and high-sensitivity C-reactive protein (hs-CRP) were obtained on days 0, 7, 14, and 28 after randomization and change over time with the two statin treatments relative to placebo was examined.

Results: Atorvastatin 80mg/d reduced ROCK activity (p=0.002 vs. placebo). This decline was rapid and significant within 2 weeks of treatment. The inhibition of ROCK by atorvastatin (80mg/d) remained significant even after controlling for changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides (p=0.01). Furthermore, there was no correlation between changes in ROCK activity and changes in LDL-C (r=0.2, p=0.25) or triglycerides (r=0.1, p=0.55). There was a modest correlation between ROCK inhibition and change in hs-CRP among patients randomized to atorvastatin 80mg/d (r=0.6, p=0.07).

Conclusions: These first-in-man findings demonstrate that high-dose atorvastatin rapidly inhibits the pro-atherogenic Rho/ROCK pathway, independent of cholesterol reduction. This inhibition may contribute to the clinical benefits of statins. Rho/ROCK may provide a useful therapeutic target in patients with atherosclerosis.

Citing Articles

Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities.

Askarizadeh F, Karav S, Jamialahmadi T, Sahebkar A Pharmacol Rep. 2024; 77(1):43-71.

PMID: 39680334 DOI: 10.1007/s43440-024-00678-2.

Association between Statin Use and Chemotherapy-Induced Cardiotoxicity: A Meta-Analysis.

Jaiswal V, Ang S, Deb N, Hanif M, Batra N, Kanagala S Medicina (Kaunas). 2024; 60(4).

PMID: 38674227 PMC: 11052115. DOI: 10.3390/medicina60040580.

Targeting the High-Density Lipoprotein Proteome for the Treatment of Post-Acute Sequelae of SARS-CoV-2.

Grote K, Schaefer A, Soufi M, Ruppert V, Linne U, Mukund Bhagwat A Int J Mol Sci. 2024; 25(8).

PMID: 38674105 PMC: 11049911. DOI: 10.3390/ijms25084522.

Efficacy of single high-dose statin prior to percutaneous coronary intervention in acute coronary syndrome: a systematic review and meta-analysis.

de Liyis B, Jagannatha G, Kosasih A, Darma I, Artha I Egypt Heart J. 2024; 76(1):49.

PMID: 38630377 PMC: 11024076. DOI: 10.1186/s43044-024-00481-7.

Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia.

Lopez-Lopez A, Valenzuela R, Rodriguez-Perez A, Guerra M, Labandeira-Garcia J, Munoz A Antioxidants (Basel). 2023; 12(7).

PMID: 37507992 PMC: 10376833. DOI: 10.3390/antiox12071454.

References

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

Seasholtz T, Majumdar M, Kaplan D, Brown J . Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res. 1999; 84(10):1186-93. DOI: 10.1161/01.res.84.10.1186. View

Liu P, Chen J, Lin L, Liao J . Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol. 2007; 49(15):1619-1624. PMC: 2615567. DOI: 10.1016/j.jacc.2006.12.043. View

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Miyata K, Shimokawa H, Kandabashi T, Higo T, Morishige K, Eto Y . Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol. 2000; 20(11):2351-8. DOI: 10.1161/01.atv.20.11.2351. View

Laufs U, Marra D, Node K, Liao J . 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999; 274(31):21926-31. DOI: 10.1074/jbc.274.31.21926. View

Amano M, Fukata Y, Kaibuchi K . Regulation and functions of Rho-associated kinase. Exp Cell Res. 2000; 261(1):44-51. DOI: 10.1006/excr.2000.5046. View

Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-504. DOI: 10.1056/NEJMoa040583. View

Laufs U, La Fata V, Plutzky J, Liao J . Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97(12):1129-35. DOI: 10.1161/01.cir.97.12.1129. View

10.

Bourcier T, Libby P . HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20(2):556-62. DOI: 10.1161/01.atv.20.2.556. View

11.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

12.

Essler M, Retzer M, Bauer M, Heemskerk J, Aepfelbacher M, Siess W . Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem. 1999; 274(43):30361-4. DOI: 10.1074/jbc.274.43.30361. View

13.

Ito T, Ikeda U, Shimpo M, Ohki R, Takahashi M, Yamamoto K . HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther. 2002; 16(2):121-6. DOI: 10.1023/a:1015701415588. View

14.

Stroes E, Koomans H, de Bruin T, Rabelink T . Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995; 346(8973):467-71. DOI: 10.1016/s0140-6736(95)91322-x. View

15.

Rikitake Y, Liao J . Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation. 2005; 111(24):3261-8. PMC: 2633592. DOI: 10.1161/CIRCULATIONAHA.105.534024. View

16.

Takemoto M, Liao J . Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21(11):1712-9. DOI: 10.1161/hq1101.098486. View

17.

Libby P, Ridker P . Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004; 116 Suppl 6A:9S-16S. DOI: 10.1016/j.amjmed.2004.02.006. View

18.

Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu P . ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest. 2008; 118(5):1632-44. PMC: 2293333. DOI: 10.1172/JCI29226. View

19.

Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui D, Yang S . Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000; 106(1):15-24. PMC: 314365. DOI: 10.1172/JCI9639. View

20.

Ridker P, Cannon C, Morrow D, Rifai N, Rose L, McCabe C . C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352(1):20-8. DOI: 10.1056/NEJMoa042378. View